Lazard Asset Management LLC Enanta Pharmaceuticals Inc Transaction History

Lazard Asset Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$60.19 - $97.37 $68,917 - $111,488	-1,145 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$41.02 - $58.65 $46,967 - $67,154	1,145 New	1,145 $65,000
Q4 2020 Feb 11, 2021	SELL	$41.16 - $47.47 $40,542 - $46,757	-985 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$43.36 - $53.53 $8,715 - $10,759	-201 Reduced 16.95%	985 $45,000
Q2 2020 Aug 13, 2020	BUY	$46.37 - $57.58 $8,161 - $10,134	176 Added 17.43%	1,186 $59,000
Q1 2020 May 14, 2020	BUY	$40.22 - $62.0 $10,457 - $16,120	260 Added 34.67%	1,010 $51,000
Q4 2019 Feb 13, 2020	BUY	$57.95 - $66.61 $32,973 - $37,901	569 Added 314.36%	750 $46,000
Q3 2019 Nov 14, 2019	BUY	$60.08 - $88.17 $10,874 - $15,958	181 New	181 $10,000
Q2 2018 Aug 13, 2018	SELL	$81.85 - $120.51 $1.56 Million - $2.3 Million	-19,058 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$57.91 - $92.15 $404,790 - $644,128	6,990 Added 57.92%	19,058 $1.54 Million
Q4 2017 Feb 13, 2018	SELL	$45.65 - $59.37 $3.73 Million - $4.85 Million	-81,647 Reduced 87.12%	12,068 $708,000
Q4 2014 Aug 29, 2019	BUY	N/A	93,715	93,715 $4.77 Million

107

18.3M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $148M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.